Achieving control of severe asthma with targeted therapy

The purpose of the study was to assess the clinical and functional parameters of patients with severe asthma to optimize drug therapy in order to improve the control. Methods. We examined 45 patients diagnosed with severe asthma: 34 (75%) women and 11 (25%) men. The median age was 56 (30; 70) years. 37 (82%) respondents had an allergic asthma phenotype, while 8 (18%) patients had non-allergic asthma. As for the comorbidities, allergic rhinitis was the most common (56%), intolerance to NSAIDs was observed in a third of the studied patients, and chronic polypous rhinosinusitis (CPRS) was diagnosed in 20 (44%) patients. Results. Each respondent was diagnosed with at least 1 marker of T2 immune response. Before the initiation of biologics, the patients experienced frequent asthma attacks daily, and a high need for SABA was determined. None of the patients had asthma symptoms under control. After 4 months, the control indicator, AST test score, improved to 22 [20; 25] points. The low FEV₁ of 65.5% (48.6; 76.8) and FEV₁/FVC of 61.4% (43.9; 72.1) before the initiation of biological therapy should be noted. However, the pulmonary function parameters improved after 4 months – the FEV₁ increased to 82% (51.0; 93.4), and FEV₁/FVC raised to 71.3% (51.2; 74.4). Conclusion. All patients were diagnosed with at least 1 marker of T2 immune response. Thus, the correct selection of patients with T2 immune response markers makes it possible to prescribe personalized drug therapy, which, in turn, ensures the achievement of control over asthma. After 4 months biological therapy, the patients noted the absence of exacerbations, a decrease in the need for SABA, and an improvement in pulmonary function.

1. Khalaf K., Paoletti G., Puggioni F. et al. Asthma from immune pathogenesis to precision medicine. Semin. Immunol. 2019; 46: 101294. DOI: 10.1016/j.smim.2019.101294.

2. Stern J., Pier J., Litonjua A.A. Asthma epidemiology and risk factors. Semin. Immunopathol. 2020; 42 (1): 5–15. DOI: 10.1007/s00281-020-00785-1.

3. Heffler E., Blasi F., Latorre M. et al. The severe asthma network in Italy: findings and perspectives. J. Allergy Clin. Immunol. Pract. 2019; 7 (5): 1462–1468. DOI: 10.1016/j.jaip.2018.10.016.

4. Global Initiative for Asthma (GINA). GINA 2023 Global Strategy for Asthma Management and Prevention. Availableat: https://ginasthma.org/2023-gina-main-report/

5. Criner G.J., Celli B.R., Brightling C.E. et al. Benralizumab for the prevention of COPD exacerbations. N. Engl. J. Med. 2019; 381 (11): 1023–1034. DOI: 10.1056/nejmoa1905248

6. Siddiqui S., Denlinger L.C., Fowler S.J. et al. Unmet needs in severe asthma subtyping and precision medicine trials. Bridging clinical and patient perspectives. Am. J. Respir. Crit. Care Med. 2019; 199 (7): 823–829. DOI: 10.1164/rccm.201809-1817PP.

7. Shogenova M.S., Hutueva S.H., Shogenova L.S. [The effectiveness of targeted therapy of various genetically engineered biological drugs in the treatment of bronchial asthma]. Terapevticheskii arkhiv. 2023; 95 (12): 1112–1118. DOI: 10.26442/00403660.2023.12.202491 (in Russian).

8. Nannini L.J. Treat to target approach for asthma. J. Asthma. 2020; 57 (6): 687–690. DOI: 10.1080/02770903.2019.1591443.

9. Peters M.C., Wenzel S.E. Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma. Lancet. 2020; 395 (10221): 371–383. DOI: 10.1016/S0140-6736(19)33005-3.

10. Schoettler N., Strek M.E. Recent advances in severe asthma: from phenotypes to personalized medicine. Chest. 2020; 157 (3): 516–528. DOI: 10.1016/j.chest.2019.10.009.

11. Castro M., Corren J., Pavord I.D. et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N. Engl. J. Med. 2018; 378 (26): 2486–2496. DOI: 10.1056/nejmoa1804092.

12. Nelson R.K., Bush A., Stokes J. et al. Eosinophilic asthma. J. Allergy Clin. Immunol. 2020; 8 (2): 465–473. DOI: 10.1016/j.jaip.2019.11.024.

13. Fajt M.L., Wenzel S.E. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J. Allergy Clin. Immunol. 2015; 135 (2): 299–310. DOI: 10.1016/j.jaci.2014.12.1871.

14. Castro M., Zangrilli J., Wechsler M.E. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir. Med. 2015; 3 (5): 355–366. DOI: 10.1016/s2213-2600(15)00042-9.

15. Liu T., Wang F., Wang G., Mao H. Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials. Front. Med. 2018; 12 (3): 340–349. DOI: 10.1007/s11684-017-0565-0.

16. Nakajima S., Kabata H., Kabashima K., Asano K. Anti-TSLP antibodies: targeting a master regulator of type 2 immune responses. Allergol. Int. 2020; 69 (2): 197–203. DOI: 10.1016/j.alit.2020.01.001.

17. FitzGerald J.M., Bleecker E., Nair P. et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2128–2141. DOI: 10.1016/s0140-6736(16)31322-8.

18. Parulekar A.D., Diamant Z., Hanania N.A. Role of biologics targeting type 2 airway inflammation in asthma: what have we learned so far? Curr. Opin. Pulm. Med. 2017; 23 (1): 3–11. DOI: 10.1097/mcp.0000000000000343.

19. Krings J.G., McGregor M.C., Bacharier L.B., Castro M. Biologics for severe asthma: treatment-specific effects are important in choosing a specific agent. J. Allergy Clin. Immunol. Pract. 2019; 7 (5): 1379–1392. DOI: 10.1016/j.jaip.2019.03.008.